Amgen announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco. Results from a one-year study in chronic migraine patients reinforced the established safety and efficacy profile of Aimo...
French biotech Abivax’s might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.
The company has announced results from the first group of patients in its most recent phase 2a trial testing the potential HIV cure treatment codenamed ABX464.
The study aimed at acc...
The treatment could relieve haemophilia B patients from factor IX replacement drugs
UniQure has enrolled the first patient in its registration trial of haemophilia B gene therapy candidate AMT-061 as it tries to keep ahead of a rival project from Spark Therapeutics/Pfizer.
The subject is the first out of around 50 subjects that will be recruited into the open-label HOPE-B trial of AMT-061, an a...
When Roche got Herceptin onto China’s national insurance program, it didn’t expect demand to surge so quickly, overwhelming its production capacity there. Now, to cope with a nationwide shortage, it’s shifting to a different manufacturing site to amp up supplies of the cancer therapy.
Roche applied to change Herceptin's existing production site for China to a high...